@article {172390, title = {DAAs therapy associated with improved hepatic fibrosis in HCV-GT4 patients co-infected with HIV.}, journal = {Expert review of gastroenterology \& hepatology}, year = {2019}, pages = {1-6}, abstract = {

BACKGROUND: The present work aimed at evaluation of the potential dynamic changes in hepatic fibrosis following treatment of chronic HCV using DAAs in patients coinfected with HIV.

PATIENTS AND METHODS: In total, 50 HCV/HIV coinfected patients [age; 34.68 {\textpm} 10.38 years, 82\% men] were included. For all included patients, liver stiffness measured using transient elastography as well as serum liver fibrosis scores; [fibrosis-4 (FIB-4) score and the aspartate aminotransferase to platelet ratio index (APRI)] were calculated at baseline and at 12 and 24-weeks following 12 weeks therapy of HCV with once daily sofosbuvir 400 mg plus daclatasvir 60 mg.

RESULTS: Most of the included patients (70\%, n = 35) were on anti-retroviral therapy. SVR24 was achieved by 93.48\% of the patients. There was significant serial improvement in baseline liver stiffness measurement (LSM), FIB-4 and APRI among responders; [LSM: baseline, 7.05 {\textpm} 4.84 kPa vs. 5.66 {\textpm} 2.63 kPa at SVR24, p \< 0.001], [FIB-4: baseline, 1.24 {\textpm} 1.08 vs. 0.93 {\textpm} 0.64 at SVR24, p 0.001) and (APRI: baseline, 0.725 {\textpm} 0.66 vs. 0.36 {\textpm} 0.19at SVR24, p 0.001) respectively.

CONCLUSION: Treatment of HCV patients coinfected with HIV using DAAs is associated with a rapid significant regression in hepatic fibrosis, as evaluated by FibroScan, FIB-4, and APRI scores.

}, author = {El-Garem, Hassan and Mohamed Abdallah and Heba Omar and Cordie, Ahmed and Shereen Abdel Alem and Mohey Eldin Elzahry, Mohamad A and doaa ghaith and Abou El-Soud, Neveen H and Kamal, Walid and Elsharkawy, Aisha and Gamal Esmat} }